Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination
Glycemic Control With Triple Pathway Approach Through Empagliflozin-Linagliptin-Metformin
Nabiqasim Industries (Pvt) Ltd
800 participants
Oct 30, 2025
INTERVENTIONAL
Conditions
Summary
The efficacy and safety of a triple-pill combination therapy for advanced type 2 diabetes care. The study aims to assess the impact of 3 Oral Anti Diabetic (OAD) drugs on metabolic control, patient compliance, weight management, quality of life, diabetic treatment satisfaction and frequency of hypoglycemic events by combining them into a fixed-dose single pill.
Eligibility
Inclusion Criteria6
- Patients of any gender
- Patients aged between 18-80 years
- Patients having HbA1c 8 % or above
- Patients diagnosed with type II diabetes (more than at least 06 months)
- Patients already on at least 02 or more anti-diabetic agents
- Patients not allergic to empagliflozin, linagliptin, or metformin
Exclusion Criteria11
- Patients with age less than 18
- Patients with Type-I diabetes
- Patients having diabetes for less than 06 months
- Patients on GLP-1 and GIP
- Patients who are pregnant or lactating females
- Patients with decompensated chronic liver disease (DCLD)
- Patients with eGFR less than 30 ml
- Patients with end-stage heart failure (NYHA Class 4)
- Patients who are allergic to empagliflozin, linagliptin, or metformin
- Patients who are not willing to consent
- Patients who are unable to give medical history
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Scarcity of local population data on triple drug combination's impact on compliance, efficacy and safety in diabetic patients
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06862739